Axsome Therapeutics, Inc.
NASDAQAXSM enters the back half of June with an unusual tension: a fresh analyst upgrade pushing the price target ceiling higher while short sellers quietly rebuild positions at the fastest pace in months. TD Cowen's Joseph Thome raised his target from $275 to $300 this week — today's action, within the last 24 hours — keeping a Buy rating on the stock. That move sits at the optimistic…
Snapshot as of 29 Jun 2026
AXSM enters the back half of June with an unusual tension: a fresh analyst upgrade pushing the price target ceiling higher while short sellers quietly rebuild positions at the fastest pace in months. TD Cowen's Joseph…
Axsome Therapeutics heads into its Q1 2026 earnings call on Friday, June 5 carrying two competing signals: a freshly settled SUNOSI patent dispute that removes a meaningful overhang, and a persistent pattern of insider…
Axsome Therapeutics heads into its May 4 Q1 report as one of the more bullishly positioned CNS names in the market, with the stock up 22% over the past month and analyst targets rising in lockstep. The analyst…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AXSM — free to start on ORTEX.
Sign up for free →Open AXSM on ORTEX